Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors

Article English OPEN
Ahn, Daniel H.; Ozer, Hatice Gulcin; Hancioglu, Baris; Lesinski, Gregory B.; Timmers, Cynthia; Bekaii-Saab, Tanios;

We previously conducted a phase-II study with selumetinib (AZD6244), a small molecule inhibitor of MEK1/2, in advanced biliary tract cancers (BTC), where the primary endpoint was response rate. Several patients experienced objective response. These findings were confirm... View more
Share - Bookmark